舒泰神(300204) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥63,214,002.99, a decrease of 33.45% compared to ¥94,983,395.63 in the same period last year[3] - The net loss attributable to shareholders was ¥2,335,039.14, an improvement of 38.05% from a loss of ¥3,769,395.63 in the previous year[3] - The net cash flow from operating activities was -¥15,273,176.15, which is a 10.33% improvement compared to -¥17,031,862.23 last year[3] - The total operating revenue for the current period is ¥63,214,002.99, a decrease of approximately 33.6% compared to ¥94,983,395.63 in the previous period[33] - The company reported a net loss of ¥411,117,990.66, slightly increasing from a loss of ¥408,785,633.30 in the previous period[31] - The company reported a net loss of CNY 4,407,104.91, compared to a net loss of CNY 3,769,395.63 in the previous period, indicating a deterioration in performance[34] - Operating profit was recorded at CNY -4,387,963.90, worsening from CNY -3,268,100.38 year-over-year[34] - Total comprehensive income amounted to CNY -34,065,021.00, significantly lower than CNY 8,418,612.81 in the prior period[34] Cash Flow and Assets - The company's cash and cash equivalents increased by ¥35,525,295.04, a rise of 65.90% due to an increase in bank deposits[7] - The cash and cash equivalents increased to ¥89,436,475.08 from ¥53,911,180.04, representing a growth of approximately 65.9%[29] - The total assets increased by 1.10% to ¥1,162,255,527.06 from ¥1,149,607,757.17 at the end of the previous year[4] - The total liabilities decreased to ¥219,559,206.21 from ¥232,846,415.32, reflecting a reduction of approximately 5.7%[30] - The ending cash and cash equivalents balance increased to CNY 89,436,475.08 from CNY 62,981,635.34 in the previous period[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,509[11] - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., holds 31.01% of shares, totaling 148,165,963 shares[11] - The second-largest shareholder, Xiangtang Group Co., Ltd., holds 7.68% of shares, totaling 36,695,008 shares, with 32,550,000 shares pledged[11] - The total number of restricted shares at the end of the period is 24,108,054, with significant increases in restricted shares for key executives[14] - The company has no major changes in the participation of top shareholders in margin trading activities[12] Research and Development - Research and development expenses decreased by 46.54% to ¥16,426,000.00, reflecting reduced investment in R&D projects[7] - Research and development expenses decreased to ¥16,408,159.79 from ¥30,691,001.31, indicating a reduction of approximately 46.4%[33] - The company reported a significant clinical trial result for STSP-0601, achieving a 12-hour effective hemostasis rate of 81.94% in hemophilia A or B patients[15] - The average number of doses required for effective hemostasis in the trial was 1.9, with 77.12% of visits requiring only 1-2 doses[15] - The safety profile of STSP-0601 was good, with 36.00% of participants reporting mild adverse events, and no serious adverse events reported[16] - The company has made progress in clinical projects, including the STSP-0601 injection for hemophilia A or B patients, which has completed the IIb phase and is now entering the III phase of clinical research[26] - The BDB-001 study for ANCA-associated vasculitis has completed all subject follow-ups and is preparing for the III phase clinical research[27] - The company plans to submit a conditional marketing application for STSP-0601 based on the positive IIb phase clinical data[26] Financing and Investments - The company raised ¥40,000,000.00 from minority shareholders during the quarter, indicating successful capital raising efforts[9] - The company received a total of RMB 60 million in initial investment from Wuxi Jinyi Yuanli Equity Investment Partnership, with RMB 40 million as capital increase and RMB 20 million as share transfer payment[21] - The company plans to apply for a loan of RMB 50 million from Beijing Rural Commercial Bank for operational turnover, with a term of 12 months[24] - The company will provide collateral for the loan using its own real estate and land use rights, with a guarantee amount of RMB 65 million[24] - The company raised CNY 80,000,000.00 through financing activities, with a net cash inflow of CNY 49,936,200.00 after outflows[36] Management Changes - The company appointed several senior management personnel on March 23, 2025, including a new deputy general manager and heads of various departments[25] - The company completed the transfer of shares from its controlling shareholder, Yizhao Technology, to Mr. Zhou Zhiwen, with the registration completed on February 25, 2025[18] - The subsidiary, Jiangsu Beijitai Biotechnology Co., Ltd., completed its business registration change and received a new business license on February 10, 2025[18] - The subsidiary, Beijing Sannuo Jiayi Biotechnology Co., Ltd., was recognized as a national high-tech enterprise on February 13, 2025[19] Other Financial Metrics - The company generated CNY 60,332,701.69 in cash from sales, down from CNY 90,313,155.91 in the prior period[35] - Cash flow from investing activities yielded a net inflow of CNY 863,486.76, compared to a net outflow of CNY -4,955,311.49 last year[36] - Basic and diluted earnings per share remained at CNY 0.00, unchanged from the previous period[35] - The company experienced a significant increase in credit impairment losses, totaling CNY -16,586.06, compared to CNY 51,282.21 previously[34]